SEQUENCE LISTING

<110> Zealand Pharma A/S

<120> Pharmaceutical composition of GLP-1/GLP-2 dual agonists

<130> P121464PCT

<160> 3

<170> PatentIn version 3.5

<210> 1
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MOD_RES
<222> (16)..(16)
<223> Xaa is Lys or D-Lys in which an albumin binding moiety [K([17-carboxy-heptadecanoyl]-isoGlu)] is conjugated to the GLP-1/GLP-2 dual agonist

<400> 1

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr
20 25 30

Asp

<210> 2
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 dual agonist peptide (Formula A)

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is Thr or Ser

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa is Thr or Ser

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is Lys or D-Lys in which an albumin binding moiety
       [K([17-carboxy-heptadecanoyl]-isoGlu)] is conjugated to the
       GLP-1/GLP-2 dual agonist

<220>
<221> MISC_FEATURE
<222> (28)..(28)
<223> Xaa is Gln, Glu, Ala, His, Tyr, Leu, Lys, Arg or Ser

<400> 2

His Xaa Glu Gly Xaa Phe Xaa Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1   5   10   15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Xaa His Lys Ile Thr
            20   25   30

Asp

<210> 3
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 dual agonist peptide (Formula B)

<220>
<221> MOD_RES

<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is Thr or Ser

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is Lys or D-Lys in which an albumin binding moiety
[K([17-carboxy-heptadecanoyl]-isoGlu)] is conjugated to the
GLP-1/GLP-2 dual agonist

<220>
<221> MISC_FEATURE
<222> (28)..(28)
<223> Xaa is Gln, Glu, Ala, His, Tyr, Leu, Lys, Arg or Ser

<400> 3

His Xaa Glu Gly Xaa Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Xaa His Lys Ile Thr
20 25 30

Asp